{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:56:56Z","timestamp":1792090616223,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,21]]},"DOI":"10.7759\/cureus.95045","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:43:04Z","timestamp":1761046984000},"source":"Crossref","is-referenced-by-count":3,"title":["Gut Microbiota-Directed Interventions in Type 2 Diabetes: A Systematic Review of Clinical Outcomes and Complication Risk"],"prefix":"10.7759","author":[{"given":"Mustafeez","family":"Ur Rehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadia","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Omer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahbaz","family":"Tashfeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska E","year":"2025","unstructured":"M\u0142ynarska E, Czarnik W, Dzie\u017ca N, et al.. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025, 26:10.3390\/ijms26031094","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2024.100287","article-title":"Deciphering the complex interplay of risk factors in type 2 diabetes mellitus: a comprehensive review","volume":"22","author":"Singh S","year":"2024","unstructured":"Singh S, Kriti M, K S A, et al.. Deciphering the complex interplay of risk factors in type 2 diabetes mellitus: a comprehensive review. Metabol Open. 2024, 22:100287. 10.1016\/j.metop.2024.100287","journal-title":"Metabol Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102436","article-title":"Current advances in the management of diabetes mellitus","volume":"10","author":"Aloke C","year":"2022","unstructured":"Aloke C, Egwu CO, Aja PM, et al.. Current advances in the management of diabetes mellitus. Biomedicines. 2022, 10:10.3390\/biomedicines10102436","journal-title":"Biomedicines"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094112","article-title":"Human gut microbiome: a connecting organ between nutrition, metabolism, and health","volume":"26","author":"Valencia S","year":"2025","unstructured":"Valencia S, Zuluaga M, Florian P\u00e9rez MC, Montoya-Quintero KF, Candamil-Cort\u00e9s MS, Robledo S. Human gut microbiome: a connecting organ between nutrition, metabolism, and health. Int J Mol Sci. 2025, 26:10.3390\/ijms26094112","journal-title":"Int J Mol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2022.0104","article-title":"Functions of gut microbiota metabolites, current status and future perspectives","volume":"13","author":"Liu J","year":"2022","unstructured":"Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C.  Functions of gut microbiota metabolites, current status and future perspectives. Aging Dis. 2022, 13:1106-26. 10.14336\/AD.2022.0104","journal-title":"Aging Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15060397","article-title":"Gut microbiota dysbiosis and its impact on type 2 diabetes: from pathogenesis to therapeutic strategies","volume":"15","author":"Yu Y","year":"2025","unstructured":"Yu Y, Ding Y, Wang S, Jiang L. Gut microbiota dysbiosis and its impact on type 2 diabetes: from pathogenesis to therapeutic strategies. Metabolites. 2025, 15:10.3390\/metabo15060397","journal-title":"Metabolites"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125486","article-title":"Gut microbiota-targeted therapeutics for metabolic disorders: mechanistic insights into the synergy of probiotic-fermented herbal bioactives","volume":"26","author":"Fan Y","year":"2025","unstructured":"Fan Y, Liu Y, Shao C, Jiang C, Wu L, Xiao J, Tang L. Gut microbiota-targeted therapeutics for metabolic disorders: mechanistic insights into the synergy of probiotic-fermented herbal bioactives. Int J Mol Sci. 2025, 26:10.3390\/ijms26125486","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/life13061247","article-title":"A critical perspective on the supplementation of Akkermansia muciniphila: benefits and harms","volume":"13","author":"Chiantera V","year":"2023","unstructured":"Chiantera V, Lagan\u00e0 AS, Basciani S, Nordio M, Bizzarri M. A critical perspective on the supplementation of Akkermansia muciniphila: benefits and harms. Life (Basel). 2023, 13:10.3390\/life13061247","journal-title":"Life (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier C","year":"2019","unstructured":"Depommier C, Everard A, Druart C, et al.. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019, 25:1096-103. 10.1038\/s41591-019-0495-2","journal-title":"Nat Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.2003176","article-title":"Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study","volume":"14","author":"Wang S","year":"2022","unstructured":"Wang S, Ren H, Zhong H, et al.. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut Microbes. 2022, 14:2003176. 10.1080\/19490976.2021.2003176","journal-title":"Gut Microbes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02254-y","article-title":"Effects of personalized diets by prediction of glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized\u00a0dietary intervention pilot trial","volume":"20","author":"Rein M","year":"2022","unstructured":"Rein M, Ben-Yacov O, Godneva A, et al.. Effects of personalized diets by prediction of glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized\u00a0dietary intervention pilot trial. BMC Med. 2022, 20:56. 10.1186\/s12916-022-02254-y","journal-title":"BMC Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac210","article-title":"Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes","volume":"107","author":"Deng X","year":"2022","unstructured":"Deng X, Zhang C, Wang P, et al.. Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes. J Clin Endocrinol Metab. 2022, 107:1888-96. 10.1210\/clinem\/dgac210","journal-title":"J Clin Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-022-02904-0","article-title":"Effects of enriched seafood sticks (heat-inactivated\u00a0B. animalis subsp. lactis\u00a0CECT 8145, inulin, omega-3) on cardiometabolic risk factors and gut microbiota in abdominally obese subjects: randomized controlled trial","volume":"61","author":"Companys J","year":"2022","unstructured":"Companys J, Calder\u00f3n-P\u00e9rez L, Pla-Pag\u00e0 L, et al.. Effects of enriched seafood sticks (heat-inactivated\u00a0B. animalis subsp. lactis\u00a0CECT 8145, inulin, omega-3) on cardiometabolic risk factors and gut microbiota in abdominally obese subjects: randomized controlled trial. Eur J Nutr. 2022, 61:3597-611. 10.1007\/s00394-022-02904-0","journal-title":"Eur J Nutr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.17583","article-title":"Microbiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: a prospective, open label, controlled, randomized, comparative, proof of concept study","volume":"12","author":"Kallapura G","year":"2024","unstructured":"Kallapura G, Prakash AS, Sankaran K, Manjappa P, Chaudhary P, Ambhore S, Dhar D. Microbiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: a prospective, open label, controlled, randomized, comparative, proof of concept study. PeerJ. 2024, 12:e17583. 10.7717\/peerj.17583","journal-title":"PeerJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.999715","article-title":"White common bean extract remodels the gut microbiota and ameliorates type 2 diabetes and its complications: a randomized double-blinded placebo-controlled trial","volume":"13","author":"Feng Y","year":"2022","unstructured":"Feng Y, Zhu J, Wang Q, et al.. White common bean extract remodels the gut microbiota and ameliorates type 2 diabetes and its complications: a randomized double-blinded placebo-controlled trial. Front Endocrinol (Lausanne). 2022, 13:999715. 10.3389\/fendo.2022.999715","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3351","article-title":"Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population","volume":"101","author":"Haro C","year":"2016","unstructured":"Haro C, Montes-Borrego M, Rangel-Z\u00fa\u00f1iga OA, et al..  Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J Clin Endocrinol Metab. 2016, 101:233-42. 10.1210\/jc.2015-3351","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0245-0","article-title":"Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-na\u00efve patients with type 2 diabetes: a pilot randomized trial","volume":"15","author":"Balfeg\u00f3 M","year":"2016","unstructured":"Balfeg\u00f3 M, Canivell S, Hanzu FA, et al.. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-na\u00efve patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis. 2016, 15:78. 10.1186\/s12944-016-0245-0","journal-title":"Lipids Health Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqaa026","article-title":"Effects of whole-grain wheat, rye, and lignan supplementation on cardiometabolic risk factors in men with metabolic syndrome: a randomized crossover trial","volume":"111","author":"Eriksen AK","year":"2020","unstructured":"Eriksen AK, Brunius C, Mazidi M, et al.. Effects of whole-grain wheat, rye, and lignan supplementation on cardiometabolic risk factors in men with metabolic syndrome: a randomized crossover trial. Am J Clin Nutr. 2020, 111:864-76. 10.1093\/ajcn\/nqaa026","journal-title":"Am J Clin Nutr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.853771","article-title":"Gut microbiota and antidiabetic drugs: perspectives of personalized treatment in type 2 diabetes mellitus","volume":"12","author":"Liu W","year":"2022","unstructured":"Liu W, Luo Z, Zhou J, Sun B. Gut microbiota and antidiabetic drugs: perspectives of personalized treatment in type 2 diabetes mellitus. Front Cell Infect Microbiol. 2022, 12:853771. 10.3389\/fcimb.2022.853771","journal-title":"Front Cell Infect Microbiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.15167\/2421-4248\/jpmh2022.63.2S3.2751","article-title":"The role of Mediterranean diet and gut microbiota in type-2 diabetes mellitus associated with obesity (diabesity)","volume":"63","author":"Ozsoy S","year":"2022","unstructured":"Ozsoy S, Sultanoglu N, Sanlidag T. The role of Mediterranean diet and gut microbiota in type-2 diabetes mellitus associated with obesity (diabesity). J Prev Med Hyg. 2022, 63:E87-92. 10.15167\/2421-4248\/jpmh2022.63.2S3.2751","journal-title":"J Prev Med Hyg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427850-gut-microbiota-directed-interventions-in-type-2-diabetes-a-systematic-review-of-clinical-outcomes-and-complication-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:43:05Z","timestamp":1761046985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427850-gut-microbiota-directed-interventions-in-type-2-diabetes-a-systematic-review-of-clinical-outcomes-and-complication-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.95045","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}